Introduction {#Sec1}
============

Breast cancer is the most common cause of cancer-related death among women worldwide with an estimated 1.15 million new cases and 411,000 breast cancer deaths around the world in 2002 \[[@CR1], [@CR2]\]. Breast cancer incidence has increased progressively in Middle Eastern and North African (MENA) populations over the last 10 years, probably due to more reliable data being collected from cancer registries and to easier access by patients to screening and diagnostic programs \[[@CR3]\]. In MENA populations, breast cancer represents \~13--30% of newly diagnosed malignancies in women and occurs at a median age of 49--52 years as compared to 63 in industrialized nations \[[@CR3]--[@CR12]\]. Breast cancer in MENA populations is characterized by younger age at onset, advanced stage and poor prognosis \[[@CR3]--[@CR12]\]. Mastectomy is performed in more than 80% of MENA women with breast cancer \[[@CR3]\].

Comparison of the clinical and tumor gene expression profiles of breast cancer between French and MENA patients showed minor but significant biological differences. A significant difference has been found in breast cancer diagnosis age (±10 years old) between French and MENA patients. This difference was more marked in Tunisian patients with a more than 13-year-old diagnosis difference. Moreover, a higher frequency of aggressive tumors was found among MENA patients as defined by the SBR histo-prognostic grade III, tumor size at diagnosis and lymph node metastasis \[[@CR13]\].

Breast cancer is an extremely complex, heterogeneous and multi-factorial disease characterized by a progressive multistep process caused by interactions of both genetic and non-genetic factors. A family history of breast cancer is the most prominent risk factor for the development of the disease \[[@CR14]\]. It is estimated that about 5--10% of all breast cancers may arise from hereditary predisposition \[[@CR15], [@CR16]\]. Investigation of multiple-case families in which breast cancer segregates with mendelian patterns of inheritance led to the identification of the tumor suppressor genes *BRCA1* (MIM 113705) \[[@CR17]\] and *BRCA2* (MIM 600185) \[[@CR18]\], which account for a substantial proportion of early-onset breast cancer but a much smaller proportion of late-onset disease \[[@CR19], [@CR20]\]. Germ-line *BRCA1* mutations are involved in about 30% of site-specific female breast cancer families, 75% of breast/ovarian cancer families, but not in male breast cancer families \[[@CR21]--[@CR23]\]. Germ-line *BRCA2* mutations are involved in about 30% specific female breast cancer families, 20--25% of breast/ovarian cancer families, and 50--80% of male/female breast cancer families \[[@CR19], [@CR20], [@CR22]--[@CR24]\]. These figures are deduced from studies on European and American populations and they are expected to be different for other populations. Cumulative risk of cancer in *BRCA* germ-line mutated carriers is highly dependant on the mutation type, the genetic background and acquired environmental factors. Life-time cumulative cancer risk in *BRCA1* mutation carriers is about 80--85% for female breast cancer, 50% for ovarian cancer, 12--40% for bilateral breast cancer \[[@CR19], [@CR25]--[@CR28]\]. Life-time cumulative cancer risk in *BRCA2* mutation carriers is about 80--85% for female breast cancer (with a later breast cancer onset), 10--25% for ovarian cancer, 6--10% for male breast cancer \[[@CR19], [@CR23]--[@CR28]\].

The frequency and spectrum of mutations within *BRCA1/2* genes vary widely among populations. In some ethnic or geographically isolated groups, founder mutations can explain the majority of inherited breast and ovarian cancer cases \[[@CR29]--[@CR32]\], whereas in other populations, germ-line mutations are randomly scattered throughout the coding sequence \[[@CR33]\].

The analysis of the *BRCA1/2* genes as well as other genes conferring increased risk of hereditary breast cancer (e.g. *TP53, PTEN, STK11, CDH1*) was poorly studied in the MENA populations. Few reports, including from our group, reported few *BRCA1/2* mutations associated with hereditary breast cancers in a small number of families from MENA countries \[[@CR34]--[@CR39]\].

The aim of this study was to investigate the mutational spectrum and frequency of germ-line *BRCA1* mutations as well as to explore the existence of population-specific recurrent or founder mutations, if any, in Tunisian breast cancer families.

Patients and methods {#Sec2}
====================

Patients and families {#Sec3}
---------------------

The current study was conducted on breast cancer families in the middle coast of Tunisia with the cooperation of two main cancer treatment centers in Sousse, Tunisia: departments of Radiation Oncology and Medical Oncology of Farhat Hached teaching Hospital, Sousse, Tunisia.

Selection criteria of familial cases were based on age at diagnosis and the number of affected first- and second-degree relatives with breast or ovarian cancer. These families' characteristics are presented in Table [1](#Tab1){ref-type="table"}. The inclusion criteria were (i) Three or more breast and/or ovarian cancers in first or second degree relatives one of which developed at an early age \<35 years or (ii) two cases with young age at diagnosis (\<35 years) and/or bilateral breast cancers and/or multiple cancers including ovarian and breast cancers. Blood samples were taken from at least one affected woman from each family. Twenty-four patients belonging to 16 families were recruited. One family presented a case of ovarian cancer and no families with male breast cancer were found. All families were apparently unrelated. Written informed consent was obtained from all subjects. Ethics committee approval was obtained from Weill Cornell Medical College in Qatar and from Farhat Hached teaching hospital of Sousse in Tunisia.Table 1Families' characteristics of our cohortFamily IDSex of probandPhenotype and age at diagnosisFamily history of breast and ovarian cancers and age at diagnosisFamily history of other cancersF1FemaleBr30M Br 35, PC Br 35LeukemiaF2FemaleBr 34S Br 20LeukaemiaF3FemaleBr 34MA Br 45, MA Br ?NoneF4FemaleBr 35MA Br 50, GM Br?BrainF5FemaleBr 46S Br 42, M Br 65NoneF7FemaleBr 36S Br 40, M Br ?, GM Br 50NoneF8FemaleBBr 38M Br 38, S Br 43NoneF9FemaleBr 42S Br 35ProstateF10FemaleBr 34M Br33NoneF11FemaleBr 53S Br 40, S Br 60NoneF12FemaleBr 29S Br 39NoneF13FemaleBr 61S Br 28NoneF14FemaleBr 47S Br 35, N Br 30Cervical, liverF15FemaleBr 42M Br 40NoneF16FemaleBr35M Br?, MA Br?ColonF17FemaleBr 49MA Br 52, MA Br 68, PC Br 42, PC Br 35, PC Ov 62Colon, Nasopharynx*Br* breast cancer, *BBr* bilateral breast cancer, *OV* ovarian cancer, *M* mother, *S* sister, *GM* grand-mother, *MA* maternal aunt, *PC* paternal cousin, *N* Niece

Methods {#Sec4}
-------

Genomic DNA was extracted from peripheral blood leukocytes using the standard salting out procedure \[[@CR40]\]. As for mutation screening, the *BRCA1* gene coding region and exon--intron boundaries were analyzed using direct DNA sequencing. The exons were amplified in 20 μl with 100 ng DNA, 1× reaction buffer, 200 μM dNTPs, 1.5 mM MgCl~2~, 0.8 μM primers (designed by Centre Jean Perrin, sequences available on request) and 1 unit Taq polymerase (except primers, all other reagents from Promega, France). PCR was performed in an thermocycler (Biometra, Germany) with an initial denaturation at 94°C for 5 min, followed by 30 cycles of (94°C 20 s, 54°C 20 s, 72°C 20 s), except for exon 7 (15 cycles of 94°C 20 s, 60°C 10 s, 72°C 20 s then 25 cycles of 94°C 20 s, 56°C 15 s, 72°C 20 s) and 23 (5 cycles of 94°C 20 s, 57°C 20 s, 72°C 20 s then 30 cycles of 94°C 20 s, 53°C 20 s, 72°C 20 s). Exon 11 was analysed in nine overlapping PCR fragments. After amplification, the PCR products were subjected to electrophoresis in a 2% agarose gel. The product was cut from the gel and purified using QIAquick gel extraction kit (Qiagen, CA). Both DNA strands were sequenced using BigDyeDeoxy terminator cycle sequencing kit (BD V3.1, Applied Biosystems) according to the manufacturer's instructions. The product was purified on a separation column (AutoSeq^TM^ G-50, Amersham Biosciences), and the templates were sequenced on an automated ABI-PRISM 310 Genetic Analyzer (Applied Biosystems). Sequence analysis was performed using Seqman software (DNAstar, Madison, WI).

Results {#Sec5}
=======

In the current study, the whole *BRCA1* gene screening was carried out on 24 patients belonging to 16 unrelated high-risk breast cancer families from the middle coast of Tunisia. These families' characteristics are presented in Table [1](#Tab1){ref-type="table"}. The median age of onset disease was 41 years, range 29--65.

Twenty-three cases were diagnosed with site-specific breast cancer and one with bilateral breast cancer. *BRCA1* gene mutation analysis was performed in these cases. *BRCA1* gene's entire coding region and its exon--intron boundaries were examined by direct sequencing.

Our results revealed six breast cancer families carrying deleterious *BRCA1* mutations with a frequency of 37.5% (6/16). In this study, a total of 19 alterations were identified in the *BRCA1* gene. An overview of the mutational spectrum is listed in Table [2](#Tab2){ref-type="table"} with both the Human Genome Organization (HUGO) approved systematic nomenclature and the Breast Cancer Information Core (BIC) traditional nomenclature.Table 2*BRCA1* Germline mutations identified in a cohort of 16 breast cancer families from the middle coast of TunisiaExon/intronSystematic nomenclatureBIC traditional nomenclatureAmino acid changeMutation typeDeleterious mutations 11c798_799delTT916delTTStop285Frameshift 11c3331_3334delCAAG3450delCAAGStop1115Frameshift 20c.5266dupC5382insCStop1829Frameshift 5c.212 + 2insGIVS5 + 2insG--SplicingSequence variants of unknown significance 8c.442-58delTIVS8-58delT--Intronic variant 11c.1067 A \> G1186A \> GQ356RMissense 11c.1456 T \> C1575T \> CF486LMissense 11c.1648A \> C1767A \> CN550HMissense 11c.2077 G \> A2196G \> AD693NMissense 11c.2082C \> T2201C \> TS694SSilent 11c.2311 T \> C2430T \> CL771LSilent 11c.2529C \> T2640C \> TR841WMissense 11c.2612C \> T2731C \> TP871LMissense 11c.3113A \> G3232A \> GE1038GMissense 11c.3119A \> G3238A \> GS1040NMissense 11c.3548C \> T3667A \> GK1183RMissense 13c.4308T \> C4427T \> CS1436SSilent 16c.4837A \> G4956A \> GS1613GMissense 18c.5117 G \> C5236G \> CG1706AMissense

Four distinct deleterious *BRCA1* mutations were identified. Three are frame-shift mutations including two small deletions (c.798_799delTT, c.3331_3334delCAAG) and one small insertion (c.5266dupC), all resulting in frame-shifts that cause premature protein termination at codon 285, 1115 and 1829, respectively. The fourth mutation was an intron 5 splice site insertion (c.212 + 2insG). The 15 remaining identified variants were missense (11), silent (3) and intronic (1) mutations classified as polymorphisms or unknown variants in the BIC database (Table [2](#Tab2){ref-type="table"}). Among these variants three were unique (observed only once): (F486L), c.1648A/C (N550H) and c.5117 G/C (G1706A).

Among the 19 *BRCA1* alterations detected in our study, the splice site mutation (c.212 + 2insG) has not been reported previously in the BIC database and is therefore considered to be novel. The deleterious mutations were located only in three exons of *BRCA1* gene with one mutation in exon 5 (c.212 + 2insG), two mutations in exon 11 (c.798_799delTT, c.3331_3334delCAAG) and one mutation in exon 20 (c.5266dupC).

The c.798_799delTT was shared by three apparently unrelated families and it accounted for 3 of the 16 (18%) *BRCA1* mutated families. The remaining mutations, including c.3331_3334delCAAG, c.5266dupC and c.212 + 2insG, were unique (i.e., each one was detected only in one family).

From the six families with *BRCA1* mutations, three (50%) had three breast cancer cases. The remaining three families (50%) had two cases of early-onset breast cancer, with a diagnosis age being ≤35 years. Five of these were families with site-specific breast cancer, and only one was a bilateral breast cancer family. The median age of onset disease was 42 years (ranged from 34--65) and 40 years (ranged from 29--61) among carriers and non-carriers, respectively.

Discussion {#Sec6}
==========

The prevalence and spectrum of *BRCA1* mutations among Middle-Eastern and North African (MENA) breast and ovarian cancer families have not yet been thoroughly studied \[[@CR39], [@CR41]\]. In the current study, we have screened the *BRCA1* gene in a cohort of 16 high-risk breast cancer families from the middle-coast of Tunisia. Interestingly, the prevalence is higher and the mutation spectrum is different as we observed only one of the four previously reported mutations \[[@CR41]\].

*BRCA1* mutations were identified in six families of our cohort with a notable 37.5% frequency. Four distinct deleterious *BRCA1* mutations were identified in our study: c.798_799delTT c.3331_3334delCAAG, c.5266dupC and c.212 + 2insG**.**

The c.798_799delTT was the most commonly observed mutation. It was shared by five patients belonging to three apparently unrelated families (F2, F8 and F10). It accounted for 3 of the 16 (18%) *BRCA1* mutated families. First, this mutation was detected in two unrelated patients belonging to families F2 and F10 with site-specific breast cancer. The same mutation was also observed in two Algerian families \[[@CR39]\]. Analyzing five microsatellite markers in and flanking the *BRCA1* locus showed a common haplotype associated with this mutation in these four carriers (data not shown) \[[@CR39]\]. Then this mutation was targeted and found in family 8. The index case, diagnosed with bilateral breast cancer at the age of 38 years, was a carrier of the c.798_799delTT mutation. In this family the mutation co-segregates with the disease and the same mutation was identified in the proband's mother and sister diagnosed with breast cancer at ages 38 and 43, respectively (Fig. [1](#Fig1){ref-type="fig"}). These findings suggest that the c.798_799delTT mutation is a Tunisian and North African founder mutation. It has been cited four times in the BIC database but only once referring to a Spanish origin (Galician). To our knowledge, it has been reported in two breast-ovarian cancer families from northeastern France \[[@CR42]\] and also in two breast-ovarian cancer families from southern Italy (Sicily) \[[@CR43]\]. Recently, it has been identified in three unrelated families from the middle and south Sardinia area with many Phoenician and Carthaginian archaeological sites \[[@CR44]\]. This restricted geographical distribution of the c.798_799delTT mutation in these close Mediterranean countries may suggest a common founder ancestor.Fig. 1Pedigree of the family 8. *Blackened circles* indicate women affected with breast cancer. The proband was designed by an *arrow*. The index case, diagnosed with bilateral breast cancer at the age of 38 years, was a carrier of the c.798_799delTT mutation. In this family the mutation co-segregates with the disease and the same mutation was identified in the proband's mother and sister diagnosed with breast cancer at ages 38 and 43, respectively

The c.5266dupC mutation in *BRCA1* exon 20 is the second most frequently reported mutation in the BIC database. Though often referred to as a Jewish founder \[[@CR45]\], this mutation is very prevalent in Central and Eastern Europe with a high frequency among different ethnic populations such as Poland (\~34%) \[[@CR46]\], Russia (14%) \[[@CR31]\], Greece (31%) \[[@CR47]\] and Brazil \[[@CR48]\]. Studies using genetic markers suggest that the same haplotype is shared by 5382insC mutation carriers and have placed the origin of the mutation back to approximately 36 generations, in the Middle Ages, somewhere in the Baltic area \[[@CR49]--[@CR51]\]. More recent data support origin from a single common ancestor \[[@CR52]\]. In our study, the c.5266dupC mutation has been found only once in a breast cancer family. The same mutation was additionally identified in a Tunisian family with a history of breast and ovarian cancer \[[@CR41]\], which suggests this mutation contributed to both breast and ovarian phenotype in the Tunisian population. Having been detected in two unrelated families, it has a prevalence of 4% (2/48) in the mutation spectrum of *BRCA1* gene. Altogether, our cumulative results suggest that c.5266dupC is also a potential recurrent mutation and may be one of the founder effects in the Tunisian population. Further studies will be necessary in order to estimate more accurately the population allele frequency and distribution of this mutation among Tunisians. Further haplotype studies of all the carriers are required to find out whether the c.5266dupC identified in our population has a common ancestor with the European mutation or whether high-frequency alleles have arisen independently more than once.

The identification of these founder and recurrent mutations in the population is an extremely important step towards the improvement of genetic counselling since molecular testing can be targeted to the founder and recurrent mutations allowing for a more rapid and less expensive test. Furthermore, families sharing identical mutations will make up a genetically homogenous subgroup allowing more significant studies of their clinical expression.

In our set, the c.3331_3334delCAAG frame shift mutation is found in one family with a 6% frequency. According to data from the BIC database, this mutation has been cited 40 times mainly with Western European, Caucasian ethnicities but only in two families of Latin American/Caribbean ancestry and one family with Egyptian ethnicity (BIC). It has been reported to occur in Spain, Portugal \[[@CR53], [@CR54]\], Australia, Canada, South America (Chilean population) \[[@CR55]\] and it is also a founder mutation in Hispanic families from Colombia \[[@CR56]\] (BIC). These observations raise the question whether *BRCA1:* c.3331_3334delCAAG is an ancient mutation that has arisen once, or has occurred several times in human history. The large geographical distribution of this mutation could suggest independent origins as demonstrated for the 4184del4 *BRCA1* mutation reported to have at least three independent origins \[[@CR50]\]. A similar finding was observed for the 1135insA *BRCA1* mutation that does not have a single origin and was found to occur in three distinct haplotype backgrounds \[[@CR57]\]. This suggests that 4184del4 and 1135insA mutations may have appeared independently several times in the human genome and may therefore be relative "hot spots" within the *BRCA1* gene \[[@CR50], [@CR57]\], this may also be the case for the c.3331_3334delCAAG mutation. Because of the complexity of the genomic structure of *BRCA1* and the scattering of the mutations throughout the gene, a screening of the whole sequence is necessary and still remains a serious technical challenge especially in developing countries. For that reasons a "pre-screen" based on the most frequent *BRCA1* mutations seen in the BIC could be considered as a first step, prior to complete gene sequence analysis \[[@CR57]\].

The c.798_799delTT, 5266dupC and c.3331_3334delCAAG mutations have been reported in different populations. The identification of these mutations in Tunisian patients can be explained by the widespread allelic heterogeneity arising from the several different colonizations that Tunisia underwent through history especially because of its location at the northernmost bulge of Africa to mark the division between the eastern and western Mediterranean Sea. It is highly conceivable that these mutations could have migrated to Tunisia and their introduction in our population might have some specific historical origins. Further genealogical studies can trace the origins of these mutations and define exactly when and how they were introduced into the Tunisian population. Determining the origins of our identified mutations may be a helpful criterion in identifying high-risk women regarding their origins or ethnic background.

The c.212 + 2insG mutation has not been described in the BIC database and to our knowledge has not been reported in any other population studies so far. Therefore, it is considered to be novel. In general, splice-site alterations lead to skipping of the complete exon following the acceptor or preceding the donor site in which the mutation is located.

For genetic counseling purposes, it is extremely important to differentiate between deleterious and polymorphic splice-site alterations. Analysis at the mRNA level will allow us to identify whether this variant leads to an aberrant splicing and can contribute to a correct and definitive clinical interpretation.

Apart from the deleterious mutations, we have also identified 15 *BRCA1* variants classified as polymorphisms or variants with unknown significance (Table [2](#Tab2){ref-type="table"}). These variants are known to occur worldwide and in populations from various geographical areas. Among these 15 variants, only Q356R and F486L were not described in our previous study \[[@CR41]\]. Three were unique: F486L**,** N550H and G1706A (observed only once). Interestingly, in the present study, the F486L and N550H variants were only identified in a healthy woman belonging to F17 family. The association of the Y179C, F486L and N550H variants together in *cis* with breast cancer has been suggested by Augello et al. with similar cases in Sicilian and Spanish patients \[[@CR43], [@CR58], [@CR59]\]. In our set, the Q356R variant, not described in the previous study, occurred with a 16% frequency. Dunning et al. reported that the *BRCA1*Arg356 allele has a higher genotype distribution in healthy controls than in breast cancer patients and may thus play a protective role in breast cancer \[[@CR60]\]. A recent study has also reported similar findings \[[@CR61]\]. These findings need deeper investigations. Further studies are required to compare their frequencies in cases and controls and thus find out whether some variants or haplotypes are breast cancer risk modifiers.

The prevalence of *BRCA1* mutations reported in our study (37.5%) is approximately 2.5 times higher than that reported initially (15.6%) \[[@CR41]\]. Furthermore, the two spectra emerging from screening in families from the northern and central parts of Tunisia are not stringently similar. This suggests that significant differences in the frequency and spectrum of *BRCA1* mutations between the different regions of the country cannot be excluded. However, the higher detection rate observed in the present study (37.5%) can be partly explained by the existence of the founder mutation. To better define the true *BRCA1* mutations frequency and spectrum in the Tunisian population, we extended the study up to 48 families by combining our data with our previously published results involving 32 families which were recruited in the same manner and selected using the same criteria as here \[[@CR41]\]. As a result, a cumulative mutation analysis from these 48 Tunisian breast/ovarian cancer families demonstrated deleterious *BRCA1* mutations in 11 families with a notable frequency of 23% (11/48). Altogether, seven different deleterious mutations were detected in the *BRCA1* gene. It is noteworthy that all found mutations are located only in three exons of *BRCA1* (exons 5, 11 and 20). Moreover, more than half (57%) of the identified mutations are located in exon 11 which spans 60% of the entire *BRCA1* coding sequence. Because of the scattering of the *BRCA1* mutations throughout the gene, a screening of the whole sequence is necessary but still remains a serious technical challenge especially in developing countries. In Tunisia, in the future planning for the effective population screening, a pre-screening of these three exons could be considered as a first step, prior to complete the whole sequence analysis. Mutation screening can be performed by different techniques which are less laborious and expensive than direct sequencing. The most used techniques are DHPLC (Denaturing High Performance Liquid Chromatography), PTT (Protein Truncation Test) and SSCP (Single Strand Conformational Polymorphism) \[[@CR44], [@CR47], [@CR56], [@CR59]\].

Unlike the spectra observed in genetically homogenous populations such as Iceland, Norway and Poland, the heterogeneous *BRCA1* mutation spectrum observed in our series of families is consistent with the genetic heterogeneity and ethnic diversity of the Tunisian population and also may reflect the existence of multiple distinct founders.

For the likelihood of having *BRCA1* mutations, two criteria are of importance: age at diagnosis, and the number and types of cancer in the family. To establish the best criteria in selecting families with a high probability of carrying *BRCA1* mutations in our population, we combined our results with those of a previously-published study about the contribution of *BRCA* mutations to breast cancer in Tunisia \[[@CR34]\]. Three out the 36 families studied in this report were excluded from our cumulative analysis (one family had a *BRCA2* mutation and two families presented male breast cancer). The stratification of families into three subgroups allowed a more detailed analysis. Hereditary site-specific female breast cancer families accounted for the large majority of this sample (69.5%; 34 out of 49 families). However, only six families were found to carry deleterious *BRCA1* mutations, accounting for the lowest mutation frequency (17.6%, 6/34). Families presenting bilateral breast cancer accounted only for 8% (4/49). In this subgroup, we found that 25% (1/4) of families were attributed to deleterious *BRCA1* mutations. In contrast, a higher rate of *BRCA1* pathogenic mutations was detected in hereditary breast/ovarian cancer families (36%, 4/11). This subgroup accounted for 22.5% (11/49) of our sample. When taking the affected relative number into account, we noticed that among mutation carriers only 36% had three or more affected relatives. These observations are not in agreement with previous studies showing that the frequency of the mutation increased with the number of affected family members.

Most studies on different populations indicate that the frequency of *BRCA1* mutations is higher in early onset breast cancer and that the mutation carriers are relatively younger than those non-mutation carriers at the age of cancer diagnosis \[[@CR62], [@CR63]\]. In this cumulative analysis, we notified that there was no significant difference between *BRCA1* mutation carriers and non-carriers at the age of cancer diagnosis (46 vs. 43.8 years).

Interestingly, among carriers, the mean age of cancer diagnosis was more than a decade lower in the breast cancer families than in the breast-ovarian cancer families (43 vs. 53.5 years). These results suggest that, in the Tunisian population, the presence of ovarian cancer, is more important than the family scale in the prediction of *BRCA1* mutations and that diagnosis age \<45 years may be a useful tool to distinguish breast (but not ovarian) cancer families having a greater likelihood of carrying *BRCA1* mutations.

Our cumulative mutation analysis showed that in 77% of the affected families, the disease could not be explained by *BRCA1* mutations and that the lowest rates occurred in breast cancer families (17% in site-specific breast cancer and 25% in bilateral breast cancer). This indicates that more efforts are necessary to better understand which kind of families should be more appropriately considered for *BRCA1* screening, particularly among those characterized by more than three female breast cancer cases. This also indicates that BRCA2 screening in these families should take priority, and also suggests that low penetrance genes are likely to contribute to susceptibility to hereditary breast/ovarian cancer in Tunisia \[[@CR64]\].

In summary, our data extend the previous ones about hereditary breast and ovarian cancer in Tunisia and highlighted the importance of the first major breast cancer susceptibility gene in the aetiology of breast cancer in our population. Our study revised the frequency of deleterious *BRCA1* mutations and consistently enlarged its spectrum in Tunisia. These studies seem to indicate that the *BRCA1* mutational spectrum is rather broad and heterogeneous in the Tunisian population. Some of these mutations appear specific and recurrent or founding ones and also reflect the existence of multiple distinct founders. In the current study, we described for the first time an example of a founder mutation in the Tunisian population (c.798_799delTT). Our cumulative mutation analysis showed that genetic testing of Tunisian high-risk breast cancer patients should be first targeted to *BRCA1* gene's exons 5, 11 and 20 where all identified mutations are located and where it is about 23% more likely to detect a mutation. In the Tunisian population, the likelihood of finding a *BRCA1* mutation is higher in breast-ovarian cancer families (36%). Early-onset and bilateral breast cancer, regardless of the family scale, may also be useful tools to distinguish breast cancer families having a greater likelihood of carrying *BRCA1* mutations with an 18.4% detection rate.

To conclude, the identification of specific and recurrent/founder mutations suggests that any given population should develop a mutation database for its programme of breast cancer screening. It is very important to collect more national data concerning *BRCA1* mutations in order to get the best estimation of the mutation distribution (especially for recurrent/founder mutations) but it is also important to evaluate if there are any regional differences even in a small country like Tunisia. It is also hoped that similar mutation surveys in other North African countries are completed so that the information can be compared and the most common mutations, playing a role in the pathogenesis of breast carcinoma, identified. This will facilitate genetic testing throughout the region.
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